Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance

Citius Pharmaceuticals IncTrade
Nano Dimension Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Nano Dimension Ltd - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Nano Dimension Ltd - ADR trades at $1.65 (market cap $350.49M). The key difference: Nano Dimension Ltd - ADR is far larger — about 17.5× Citius Pharmaceuticals Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRNNDM
Market Cap
$20.01M$350.49M
Sector
HealthTechnology
52-Week High
$1.82$2.14
52-Week Low
$0.48$1.21
Enterprise Value
$16.23M-$54.35M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Nano Dimension Ltd - ADR

NNDM trades at $1.655, up 1.53% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of -$0.03, beating expectations, while revenue grew to $102.44M in 2025. However, net income remains deeply negative at -$293.30M, and cash flow from operations is negative. Recent strategic moves include selling MarkForged to Stratasys and cost-saving initiatives to reduce cash burn.

Outlook: Potential upside from strategic divestitures and cost cuts, but high execution risk and persistent losses pose significant challenges. Investors should weigh the low P/B of 0.73 against sustained profitability concerns and shareholder disputes highlighted in recent news.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Nano Dimension Ltd - ADR

Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.

Read more on NNDM